In the latest trading session, Pfizer (PFE - Free Report) closed at $46.04, marking a -0.07% move from the previous day. This move lagged the S&P 500's daily gain of 0.03%.
Coming into today, shares of the drugmaker had gained 0.85% in the past month. In that same time, the Medical sector gained 2.3%, while the S&P 500 gained 3.02%.
PFE will be looking to display strength as it nears its next earnings release. In that report, analysts expect PFE to post earnings of $1.07 per share. This would mark year-over-year growth of 48.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $21.61 billion, up 78.17% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $4.06 per share and revenue of $79.78 billion. These results would represent year-over-year changes of +82.88% and +67.45%, respectively.
Any recent changes to analyst estimates for PFE should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.27% lower. PFE is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, PFE currently has a Forward P/E ratio of 11.35. For comparison, its industry has an average Forward P/E of 14.7, which means PFE is trading at a discount to the group.
Meanwhile, PFE's PEG ratio is currently 1.62. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.2 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 121, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
In the latest trading session, Pfizer (PFE - Free Report) closed at $46.04, marking a -0.07% move from the previous day. This move lagged the S&P 500's daily gain of 0.03%.
Coming into today, shares of the drugmaker had gained 0.85% in the past month. In that same time, the Medical sector gained 2.3%, while the S&P 500 gained 3.02%.
PFE will be looking to display strength as it nears its next earnings release. In that report, analysts expect PFE to post earnings of $1.07 per share. This would mark year-over-year growth of 48.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $21.61 billion, up 78.17% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $4.06 per share and revenue of $79.78 billion. These results would represent year-over-year changes of +82.88% and +67.45%, respectively.
Any recent changes to analyst estimates for PFE should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.27% lower. PFE is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, PFE currently has a Forward P/E ratio of 11.35. For comparison, its industry has an average Forward P/E of 14.7, which means PFE is trading at a discount to the group.
Meanwhile, PFE's PEG ratio is currently 1.62. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.2 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 121, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Get the latest research report on PFE - FREE